Creating disease-targeted therapies for children with cancer requires a better pathway for moving from the bench to the bedside.
As the recently selected chair of the Children's Oncology Group (COG), a group of more 200 centers that brings together 5,000 international experts in childhood cancer, I am in constant contact with leading researchers across the country. There are great opportunities ahead to improve the outcome for children with cancer, and we are hard at work trying to speed the timeline so the most promising new therapies can move forward. We are working on creating better pathways for disease-targeted therapies for children with cancer, and are focusing our efforts on transforming how new discoveries can move from the bench to the bedside, a process called translational research.
For more than eight years I led a group of 21 institutions that performed the initial evaluation of new drugs for children with cancer. We conducted more than 25 Phase I studies; these studies are the first clinical trials of new anticancer drugs in children whose cancer has recurred despite best-known treatments. I thus have direct knowledge of the investigational new drug trials being conducted not only at Children's Hospital, but at centers worldwide. This allows me to serve as a resource on experimental cancer treatment for Children's Hospital clinicians. For the child whose cancer has recurred, these are the kinds of trials they often seek out.
Even though we have come a long way in our ability to cure children with many types of cancer, we must still strive to find cures for all children. We also must develop treatments that have fewer side effects. Together with the COG, doctors at Children's Hospital are helping to lead the way in this effort.
- Education and Training
MD - Cornell University Medical College, New York, NY
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
National Cancer Institute, Washington, DC
PediatricsPediatric Hematology-OncologyClinical Pharmacology
- Titles and Academic Titles
Chief, Division of Clinical Pharmacology and Therapeutics
Director, Experimental Therapeutics in Oncology
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
- Centers and Programs
- Research Interests
Widemann BC, Adamson PC. Fundamentals of Cancer Chemotherapy. In: Carroll WL, Finlay JL, editors. Cancer in Children and Adolescents. Boston: Jones and Bartlett; 2010. p. 95-112.
Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: Revolution or evolution? Eur J Cancer. 2008 Jan;44(1):8-11.
Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, et al. Phase I study of sorafenib in children with refractory solid tumors: a Children's Oncology Group phase I consortium trial [abstract]. ASCO Meeting Abstracts; 2009 May 20, 2009;27(15S):10012-.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, et al. Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: a Children's Oncology Group phase I consortium study [abstract]. ASCO Meeting Abstracts; 2009 May 20, 2009;27(15S):10017-.
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT Jr, et al. A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: a Children's Oncology Group phase I consortium study [abstract]. ASCO Meeting Abstracts; 2009 May 20, 2009;27(15S):10013-.
Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, et al. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg. 2010 May 1;110(5):1383-92. Cited in PubMed: PMID 20418300. Read the article
Norris RE, Adamson PC. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. Cancer Chemother Pharmacol. 2010 May;65(6):1125-30. Epub 2009 Sep 27. Cited in PubMed: PMID 19784838. Read the abstract
Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of Vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Jul 6. Cited in PubMed: PMID 20606092. Read the abstract
Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2369-73. Epub 2010 Jul 3. Read the abstract.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomi VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. Pediatr Blood Cancer. 2010 Apr;54(4):538-45. Read the abstract
Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, et al. Days in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Clin Cancer Res. Epub 2010 Jan 12. Read the abstract
Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. Epub 2010 Jan 1. Read the abstract
Mondick J, Johnson B, Haberer L, Sale M, Adamson P, Coté C, et al. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months. Eur J Clin Pharmacol. [10.1007/s00228-009-0730-8]. 2010;66(1):77-86. Read the abstract
Posters and Presentations
Adamson P. Cancer drug development: 21st century science, 20th century clinical trials [grand rounds]. Texas Children's Cancer Center; 2009 Jan 22; Houston.
- Editorial and Academic Positions
Journal of Clinical Oncology
Pediatric Blood & Cancer
Pediatric Hematology and Oncology
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research
Journal of Pediatric Hematology/Oncology
Journal of the National Cancer Institute
2007-present, CHOP Task Force on Industrial Relations Policy
CHOP Research Subject Recruitment Committee
CHOP Grants & Contracts Compliance Sub-committee
CHOP Research Compliance Oversight Committee
- Editorial and Academic Positions